Alnylam Pharmaceuticals (ALNY) EPS (Diluted) Growth (1y) (2020 - 2026)
Alnylam Pharmaceuticals (ALNY) EPS (Diluted) Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 8.02% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -4.52% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 96.09% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 144.25% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -99.90% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -11.18% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 315.14% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 96.41% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 315.14% |
| Mar 31, 2026 | 1,158.84% |
| Dec 31, 2025 | 226.22% |
| Sep 30, 2025 | 345.60% |
| Jun 30, 2025 | -280.73% |
| Mar 31, 2025 | 73.07% |
| Dec 31, 2024 | 40.55% |
| Sep 30, 2024 | -177.12% |
| Jun 30, 2024 | 93.98% |
| Mar 31, 2024 | 62.74% |
| Dec 31, 2023 | 35.27% |
| Sep 30, 2023 | 133.86% |
| Jun 30, 2023 | 3.50% |
| Mar 31, 2023 | 29.73% |
| Dec 31, 2022 | 21.86% |
| Sep 30, 2022 | -93.57% |
| Jun 30, 2022 | -42.56% |
| Mar 31, 2022 | -16.69% |
| Dec 31, 2021 | -3.02% |
| Sep 30, 2021 | 21.40% |